Zacks Investment Research downgraded shares of Imperva (NASDAQ:IMPV) from a buy rating to a hold rating in a research note issued to investors on Wednesday, January 10th.
According to Zacks, “Imperva Inc. is engaged in the development of protection software and services for business applications and databases. The Company delivers innovative technology to give full audit accountability and separation of duties to meet regulatory compliance. It offers SecureSphere Data Security Suite to protect sensitive data from hackers and malicious insiders along with providing a fast and cost-effective route to regulatory compliance and establishes a repeatable process for data risk management. The Company’s SecureSphere offers database security solutions to secure sensitive data stored in databases, File Security solutions to protect sensitive files on file servers, storage devices, content repositories, and meet regulatory compliance mandates and Web Application Security solutions to protect web applications from cyber attacks. Imperva Inc. is headquartered in Redwood Shores, California. “
Several other brokerages have also recently commented on IMPV. Wells Fargo & Co cut shares of Imperva from an outperform rating to a market perform rating in a research note on Monday, October 9th. Imperial Capital dropped their target price on shares of Imperva from $57.00 to $50.00 and set an outperform rating for the company in a research report on Tuesday, October 10th. Morgan Stanley reiterated an underweight rating and set a $39.00 target price on shares of Imperva in a research report on Thursday, November 9th. Piper Jaffray Companies lowered shares of Imperva from an overweight rating to a neutral rating and set a $42.00 target price for the company. in a research report on Monday, October 16th. Finally, Royal Bank of Canada reiterated a buy rating and set a $49.00 target price on shares of Imperva in a research report on Wednesday, October 18th. Three analysts have rated the stock with a sell rating, eight have given a hold rating and nine have issued a buy rating to the company’s stock. Imperva has a consensus rating of Hold and a consensus target price of $51.86.
Imperva (NASDAQ:IMPV) last issued its quarterly earnings data on Wednesday, November 8th. The software maker reported $0.33 EPS for the quarter, beating the consensus estimate of $0.22 by $0.11. The company had revenue of $83.89 million during the quarter, compared to analysts’ expectations of $83.79 million. Imperva had a net margin of 3.04% and a negative return on equity of 8.52%. Imperva’s revenue for the quarter was up 22.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.08 earnings per share. analysts expect that Imperva will post -0.52 earnings per share for the current fiscal year.
A number of large investors have recently bought and sold shares of IMPV. SG Americas Securities LLC bought a new stake in Imperva during the 3rd quarter valued at $134,000. First Quadrant L P CA purchased a new position in Imperva during the 3rd quarter valued at $136,000. Ameritas Investment Partners Inc. increased its position in Imperva by 18.7% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,940 shares of the software maker’s stock valued at $141,000 after purchasing an additional 464 shares during the period. Migdal Insurance & Financial Holdings Ltd. increased its position in Imperva by 26.2% during the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 4,177 shares of the software maker’s stock valued at $201,000 after purchasing an additional 866 shares during the period. Finally, Amalgamated Bank purchased a new position in Imperva during the 2nd quarter valued at $206,000. Institutional investors own 96.93% of the company’s stock.
Imperva Company Profile
Imperva, Inc provides cyber-security solutions that protect business-critical data and applications whether in the cloud or on premises. The Company is engaged in the development, marketing, sales, service and support of cyber-security solutions. The Company’s products include its Imperva SecureSphere Paltform, Imperva CounterBreach and Imperva Camouflage for enterprise data centers, and Imperva Incapsula offering for cloud-based security services.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Imperva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imperva and related companies with MarketBeat.com's FREE daily email newsletter.